
|Videos|October 25, 2013
Ovarian Cancer Maintenance Therapy With Bevacizumab
Author(s)Robert A. Burger, MD
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
Advertisement
Clinical Pearls
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.
- In frontline trials, bevacizumab was administered with a maximum number of treatment cycles beyond chemotherapy
- In second-line trials, maintenance therapy was continued until disease progression
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
4
Reviewing Long-Term CLL Treatment With BTK Inhibitor Zanubrutinib
5









































